Merge Healthcare CEO Sells $59,500 in Stock (MRGE)
Merge Healthcare (NASDAQ:MRGE) CEO Justin C. Dearborn sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $2.38, for a total transaction of $59,500.00. Following the sale, the chief executive officer now directly owns 350,000 shares in the company, valued at approximately $833,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Merge Healthcare (NASDAQ:MRGE) traded up 1.28% on Friday, hitting $2.37. The stock had a trading volume of 310,852 shares. Merge Healthcare has a 1-year low of $1.97 and a 1-year high of $4.57. The stock has a 50-day moving average of $2.34 and a 200-day moving average of $2.3. The company’s market cap is $226.8 million.
Merge Healthcare (NASDAQ:MRGE) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.02) by $0.07. The company had revenue of $53.80 million for the quarter, compared to the consensus estimate of $53.30 million. During the same quarter in the prior year, the company posted $0.01 earnings per share. The company’s quarterly revenue was down 5.9% on a year-over-year basis. On average, analysts predict that Merge Healthcare will post $0.15 earnings per share for the current fiscal year.
Separately, analysts at Topeka Capital Markets initiated coverage on shares of Merge Healthcare in a research note on Thursday, June 12th. They set a “buy” rating and a $3.00 price target on the stock.
Merge Healthcare Incorporated (NASDAQ:MRGE) develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians.
Receive News & Ratings for Merge Healthcare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merge Healthcare Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.